PMID- 35739183
OWN - NLM
STAT- MEDLINE
DCOM- 20220627
LR  - 20220829
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 12
IP  - 1
DP  - 2022 Jun 23
TI  - Terminalia catappa aqueous leaf extract reverses insulin resistance, improves 
      glucose transport and activates PI3K/AKT signalling in high 
      fat/streptozotocin-induced diabetic rats.
PG  - 10711
LID - 10.1038/s41598-022-15114-9 [doi]
LID - 10711
AB  - Rising prevalence of type 2 diabetes mellitus (T2DM) in sub-Saharan Africa has 
      necessitated surveys of antidiabetic medicinal plants. This study assessed the 
      antidiabetic mechanism of Terminalia catappa aqueous leaf extract (TCA) in high 
      fat/low dose streptozotocin-induced type 2 diabetic rats. T2DM was induced by a 
      combination of high-fat diet and low dose STZ (30 mg/kg bw) and the animals were 
      administered with TCA (400 and 800 mg/kg bw) orally daily for 28 days. 
      Biochemical parameters and indices for diabetes including renal function tests 
      and pancreatic histology were evaluated. Relative expression of hepatic insulin 
      resistance, signalling and glucose transport genes were also assessed. Induction 
      of T2DM resulted in significant (p < 0.05) weight loss, dysregulated glucose 
      level and clearance, electrolyte imbalance and disrupted diabetic biochemical 
      parameters. Diabetes onset also perturbed beta-cell function and insulin resistance 
      indices, damaged pancreas microanatomy, while disrupting the expression of 
      insulin receptor substrate 1 (IRS-1), phosphatidylinositol 3-kinase (PI3K), 
      protein kinase B (AKT) and glucose transporter isoform 4 (GLUT-4) mRNA. Oral 
      treatment of diabetic animals with TCA significantly (p < 0.05) ameliorated 
      alterations due to T2DM induction in a manner comparable with glibenclamide. 
      These results suggest TCA exerts its antidiabetic action by reversing insulin 
      resistance, improving glucose transport and activating PI3K/AKT signalling.
CI  - (c) 2022. The Author(s).
FAU - Iheagwam, Franklyn Nonso
AU  - Iheagwam FN
AD  - Department of Biochemistry, Covenant University, P.M.B. 1023, Ota, Ogun State, 
      Nigeria. franklyn.iheagwam@covenantuniversity.edu.ng.
AD  - Covenant University Public Health and Wellbeing Research Cluster (CUPHWERC), 
      Covenant University, P.M.B. 1023, Ota, Ogun State, Nigeria. 
      franklyn.iheagwam@covenantuniversity.edu.ng.
FAU - Iheagwam, Olawumi Toyin
AU  - Iheagwam OT
AD  - Geniebook Associates, Ikeja, Lagos State, Nigeria.
FAU - Onuoha, Michael Kemjika
AU  - Onuoha MK
AD  - Covenant University Public Health and Wellbeing Research Cluster (CUPHWERC), 
      Covenant University, P.M.B. 1023, Ota, Ogun State, Nigeria.
AD  - Covenant University Health Centre, Covenant University, P.M.B. 1023, Ota, Ogun 
      State, Nigeria.
FAU - Ogunlana, Olubanke Olujoke
AU  - Ogunlana OO
AD  - Department of Biochemistry, Covenant University, P.M.B. 1023, Ota, Ogun State, 
      Nigeria.
AD  - Covenant University Public Health and Wellbeing Research Cluster (CUPHWERC), 
      Covenant University, P.M.B. 1023, Ota, Ogun State, Nigeria.
FAU - Chinedu, Shalom Nwodo
AU  - Chinedu SN
AD  - Department of Biochemistry, Covenant University, P.M.B. 1023, Ota, Ogun State, 
      Nigeria.
AD  - Covenant University Public Health and Wellbeing Research Cluster (CUPHWERC), 
      Covenant University, P.M.B. 1023, Ota, Ogun State, Nigeria.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220623
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Plant Extracts)
RN  - 5W494URQ81 (Streptozocin)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Animals
MH  - *Diabetes Mellitus, Experimental/drug therapy/metabolism
MH  - *Diabetes Mellitus, Type 2/chemically induced/drug therapy/metabolism
MH  - Glucose/metabolism
MH  - *Hypoglycemic Agents/therapeutic use
MH  - Insulin/metabolism
MH  - *Insulin Resistance
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - *Plant Extracts/therapeutic use
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Rats
MH  - Streptozocin
MH  - *Terminalia/chemistry
PMC - PMC9226017
COIS- The authors declare no competing interests.
EDAT- 2022/06/24 06:00
MHDA- 2022/06/28 06:00
PMCR- 2022/06/23
CRDT- 2022/06/23 23:20
PHST- 2022/03/23 00:00 [received]
PHST- 2022/06/17 00:00 [accepted]
PHST- 2022/06/23 23:20 [entrez]
PHST- 2022/06/24 06:00 [pubmed]
PHST- 2022/06/28 06:00 [medline]
PHST- 2022/06/23 00:00 [pmc-release]
AID - 10.1038/s41598-022-15114-9 [pii]
AID - 15114 [pii]
AID - 10.1038/s41598-022-15114-9 [doi]
PST - epublish
SO  - Sci Rep. 2022 Jun 23;12(1):10711. doi: 10.1038/s41598-022-15114-9.